• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » European Commission and Mario Monti seek to increase patient access to generic medicines

European Commission and Mario Monti seek to increase patient access to generic medicines

February 8, 2012
CenterWatch Staff

The European Generic Medicines Association (EGA) and Assogenerici, the Italian association for generic medicines, welcome the European Commission’s formal call on Italy to comply with European Union rules on the marketing authorization of generic medicines.

The European Commission (EC) infringement procedure started last year, following the EGA and Assogenerici’s official complaint to the EC against the delays in granting market authorization of generic medicines caused by incorrect linkage to intellectual property rights. Italy’s non-compliance with EU rules on marketing authorization and patent linkage provision in its Intellectual Property Code have led to lengthy delays for generic medicine manufacturers to access the market.

As stated by the EC in the pharmaceutical sector inquiry report, linking the marketing authorization process of generic medicines to intellectual property rights of the originator product (“patent linkage”) is a clear abuse of the EU regulatory system.

“We hope that this is the final step of the process and that very soon the patent linkage in the Italian Intellectual Property Code will be removed,” said Greg Perry, EGA director general.

Both associations also welcome the move from the Italian government headed by Mario Monti to tackle patent linkage in its Intellectual Property Code as the decision was made to delete article 68(1-bis).

“It is a substantial fact that, in laying down the foundations of the country's economic recovery, with the Liberalization Decree, Monti’s government has decided to include measures that expand the role of generic medicines, helping the Italian NHS to guarantee broader access to pharmaceutical care now and in the near future,” said Giorgio Foresti, president of Assogenerici. “By removing the obstacle represented by article 68 (1-bis) the government has not only responded to a specific request from the EC, but a new wave of competition is going to be injected into the market by getting rid of any patent linkage attempts.”

In addition, both associations call for the possible future insertion of a clear provision in the legislation stating that the Italian medicines agency (AIFA) should not take into account any patent issue in the marketing authorization process.

“In this time of severe economic difficulty faced by European citizens and public health authorities, it is of crucial importance that patients can access affordable treatment with no unnecessary delays. Delays in access to generic medicines were deemed unacceptable by the pharmaceutical sector inquiry and the economic crisis makes such blocks as patent linkage totally unjustifiable,” Perry concluded.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing